OptimizeRx Corporation provided earnings guidance for the first quarter of 2024, for the quarter, the company expects revenue to increase over 40% year-over-year and come in between $18.5 million and $19.2 million with a GAAP net loss between $8.2 million - $7.0 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
12.69 USD | -1.25% | +17.39% | -11.32% |
14/05 | Transcript : OptimizeRx Corporation, Q1 2024 Earnings Call, May 14, 2024 | |
14/05 | OptimizeRx Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-11.32% | 23Cr | |
+34.54% | 47TCr | |
+27.57% | 27TCr | |
+6.66% | 14TCr | |
+32.61% | 9.61TCr | |
+6.99% | 9.25TCr | |
+61.15% | 6.01TCr | |
+18.75% | 4.8TCr | |
+24.94% | 3.79TCr | |
+0.13% | 3.57TCr |
- Stock Market
- Equities
- OPRX Stock
- News OptimizeRx Corporation
- OptimizeRx Corporation Provides Earnings Guidance for the First Quarter of 2024